ProPhase Labs (PRPH)
(Delayed Data from NSDQ)
$4.71 USD
-0.24 (-4.85%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.73 +0.02 (0.42%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
PRPH 4.71 -0.24(-4.85%)
Will PRPH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PRPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRPH
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
PRPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
ProPhase Labs, Inc. (PRPH) Beats Q1 Earnings and Revenue Estimates
Other News for PRPH
ProPhase Labs to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024
ProPhase Labs Unveils Project ZenQ-AI
ProPhase Labs unveils Project ZenQ-AI
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
ProPhase Labs reports progress on commercialization of BE-Smart test